Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to assess the safety of delivering concurrent adjuvant
chemoradiation or immuno-radiation therapy after EMR/ESD in pT1b/T2N0 esophageal cancer
patients. The main objectives of the study are:
1. Assess the feasibility of enrolling 10 patients.
2. Assess the safety of delivering concurrent adjuvant chemoradiation or immunoradiation
therapy after EMR/ESD in pT1b/T2N0 esophageal cancer patients
Phase:
Phase 1
Details
Lead Sponsor:
University of Manitoba
Collaborators:
AstraZeneca CancerCare Manitoba Manitoba Medical Service Foundation